King BJ, et al. – This trial illustrated the utility of oral direct thrombin and factor Xa inhibitors (termed direct oral anticoagulants [DOACs]) in patients with calciphylaxis. The findings indicated that DOACs were safe and well tolerated, in the initial experience. Improvement or resolution of calciphylaxis in response to therapy that included DOACs was reported in several patients. The degree of renal impairment ought to guide in the selection of DOAC. Its therapeutic efficacy was to be investigated via advanced research.